The PI3K/Akt pathway interacts with ERα and is often aberrantly upregulated in breast cancers, therefore a promising therapeutic strategy is to inhibit the molecular target of rapamycin (mTOR), a key downstream effector of the PI3K enzyme. The gene discussed is AKT1; the disease is breast carcinoma.